Kardiologicka ambulance Brno s.r.o.
- Address
- lock Available on a paid plan
Kardiologicka ambulance Brno s.r.o.
Kardiologicka ambulance Brno s.r.o. is a specialized cardiology research center in the Czech Republic with expertise in advanced cardiovascular clinical trials. The center focuses on investigating novel therapeutic approaches for heart failure and cardiovascular disease prevention, contributing to the development of innovative treatments that address unmet needs in cardiac care.
- Heart failure with reduced and preserved ejection fraction (HFrEF/HFmrEF/HFpEF) treatment optimization
- Mineralocorticoid receptor antagonist therapies and finerenone research
- Primary cardiovascular event prevention in high-risk populations with elevated lipoprotein(a)
The center's research portfolio encompasses both acute decompensated heart failure management and long-term cardiovascular risk reduction strategies. With particular emphasis on patients intolerant to conventional therapies, the facility evaluates cutting-edge pharmacological interventions including RNA-based lipid-lowering therapies and novel non-steroidal mineralocorticoid receptor antagonists, positioning itself at the forefront of contemporary cardiovascular research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Amgen Inc.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kardiologicka ambulance Brno s.r.o.
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 2 | Unknown | 2024-10-08 | 2025-09-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.